Absci to Participate in Upcoming Investor Conferences
Absci (Nasdaq: ABSI), a data-first generative AI drug creation company, has announced its participation in two upcoming investor conferences in April 2025:
- H.C. Wainwright 2nd Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference - Fireside chat scheduled for Wednesday, April 2 at 10:30 a.m. ET / 7:30 a.m. PT
- 24th Annual Needham Virtual Healthcare Conference - Fireside chat scheduled for Tuesday, April 8 at 3:45 p.m. ET / 12:45 p.m. PT
Investors and interested parties can access both live and archived webcasts of these fireside chat sessions through Absci's investor relations website at investors.absci.com.
Absci (Nasdaq: ABSI), un'azienda che crea farmaci utilizzando l'IA generativa con un approccio basato sui dati, ha annunciato la sua partecipazione a due conferenze per investitori in programma ad aprile 2025:
- 2° Conferenza Virtuale Annuale sulla Scoperta e Sviluppo di Farmaci Basati sull'Intelligenza Artificiale di H.C. Wainwright - Chat informale programmata per mercoledì 2 aprile alle 10:30 ET / 7:30 PT
- 24° Conferenza Virtuale Annuale sulla Sanità di Needham - Chat informale programmata per martedì 8 aprile alle 15:45 ET / 12:45 PT
Gli investitori e le parti interessate possono accedere sia alle trasmissioni in diretta che a quelle archiviate di queste sessioni di chat informale attraverso il sito web delle relazioni con gli investitori di Absci all'indirizzo investors.absci.com.
Absci (Nasdaq: ABSI), una empresa de creación de fármacos basada en IA generativa y centrada en datos, ha anunciado su participación en dos conferencias para inversores que se llevarán a cabo en abril de 2025:
- 2ª Conferencia Virtual Anual sobre Descubrimiento y Desarrollo de Fármacos Basados en Inteligencia Artificial de H.C. Wainwright - Charla programada para el miércoles 2 de abril a las 10:30 a.m. ET / 7:30 a.m. PT
- 24ª Conferencia Virtual Anual de Salud de Needham - Charla programada para el martes 8 de abril a las 3:45 p.m. ET / 12:45 p.m. PT
Los inversores y partes interesadas pueden acceder tanto a las transmisiones en vivo como a las grabadas de estas sesiones de charla a través del sitio web de relaciones con inversores de Absci en investors.absci.com.
Absci (Nasdaq: ABSI), 데이터 중심의 생성 AI 약물 개발 회사가 2025년 4월에 열리는 두 개의 투자자 회의에 참여한다고 발표했습니다:
- H.C. Wainwright 제2회 인공지능 기반 약물 발견 및 개발 가상 회의 - 4월 2일 수요일 오전 10:30 ET / 오전 7:30 PT에 진행될 예정인 화상 대화
- 24회 Needham 가상 헬스케어 회의 - 4월 8일 화요일 오후 3:45 ET / 오후 12:45 PT에 진행될 예정인 화상 대화
투자자 및 관심 있는 분들은 Absci의 투자자 관계 웹사이트인 investors.absci.com을 통해 이 화상 대화 세션의 생중계 및 아카이브를 모두 접근할 수 있습니다.
Absci (Nasdaq: ABSI), une entreprise de création de médicaments utilisant l'IA générative et axée sur les données, a annoncé sa participation à deux conférences pour investisseurs prévues en avril 2025 :
- 2ème Conférence Virtuelle Annuelle sur la Découverte et le Développement de Médicaments Basés sur l'Intelligence Artificielle de H.C. Wainwright - Discussion informelle prévue pour le mercredi 2 avril à 10h30 ET / 7h30 PT
- 24ème Conférence Virtuelle Annuelle sur la Santé de Needham - Discussion informelle prévue pour le mardi 8 avril à 15h45 ET / 12h45 PT
Les investisseurs et les parties intéressées peuvent accéder aux diffusions en direct et archivées de ces discussions informelles via le site web des relations avec les investisseurs d'Absci à l'adresse investors.absci.com.
Absci (Nasdaq: ABSI), ein datengestütztes Unternehmen zur Erstellung von Medikamenten mit generativer KI, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im April 2025 angekündigt:
- 2. Virtuelle Konferenz zur Entdeckung und Entwicklung von Medikamenten auf Basis künstlicher Intelligenz von H.C. Wainwright - Kamin-Gespräch geplant für Mittwoch, den 2. April um 10:30 Uhr ET / 7:30 Uhr PT
- 24. Virtuelle Gesundheitskonferenz von Needham - Kamin-Gespräch geplant für Dienstag, den 8. April um 15:45 Uhr ET / 12:45 Uhr PT
Investoren und Interessierte können sowohl auf die Live- als auch auf die archivierten Webcasts dieser Kamin-Gespräche über die Investor Relations-Website von Absci unter investors.absci.com zugreifen.
- None.
- None.
VANCOUVER, Wash. and NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences.
- H.C. Wainwright 2nd Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference
Fireside chat on Wednesday, April 2 at 10:30 a.m. Eastern Time / 7:30 a.m. Pacific Time
- 24th Annual Needham Virtual Healthcare Conference
Fireside chat on Tuesday, April 8 at 3:45 p.m. Eastern Time / 12:45 p.m. Pacific Time
Interested parties may access live and archived webcasts of the fireside chat sessions on the company’s investor relations website at: investors.absci.com.
About Absci
Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Absci’s headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit www.absci.com and follow us on LinkedIn (@absci), X (Twitter) (@Abscibio), and YouTube.
Investor Contact
Alex Khan
VP, Finance & Investor Relations
investors@absci.com
Media Contact
press@absci.com
FAQ
When is Absci (ABSI) presenting at the H.C. Wainwright AI Drug Discovery Conference in 2025?
What time is Absci's (ABSI) presentation at the Needham Healthcare Conference 2025?
How can investors watch Absci's (ABSI) investor conference presentations?
Which investor conferences is Absci (ABSI) attending in April 2025?
